Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Intangibles (2018 - 2025)

Historic Intangibles for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $8532.0.

  • China SXT Pharmaceuticals' Intangibles fell 4633.29% to $8532.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8532.0, marking a year-over-year decrease of 4633.29%. This contributed to the annual value of $11808.0 for FY2025, which is 3818.12% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Intangibles stood at $8532.0 for Q3 2025, which was down 4633.29% from $11808.0 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Intangibles registered a high of $85728.0 during Q1 2022, and its lowest value of $8532.0 during Q3 2025.
  • Its 5-year average for Intangibles is $34747.4, with a median of $25191.0 in 2023.
  • In the last 5 years, China SXT Pharmaceuticals' Intangibles skyrocketed by 807.56% in 2021 and then crashed by 6749.25% in 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' Intangibles (Quarter) stood at $42353.0 in 2021, then decreased by 27.46% to $30724.0 in 2022, then decreased by 26.72% to $22514.0 in 2023, then dropped by 29.39% to $15898.0 in 2024, then tumbled by 46.33% to $8532.0 in 2025.
  • Its Intangibles stands at $8532.0 for Q3 2025, versus $11808.0 for Q1 2025 and $15898.0 for Q3 2024.